Status:
UNKNOWN
Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes
Lead Sponsor:
Wonju Severance Christian Hospital
Conditions:
Type2 Diabetes
Remodeling, Ventricular
Eligibility:
All Genders
30-80 years
Phase:
PHASE4
Brief Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated cardiovascular and renal protection in patients with type 2 diabetes (T2D); however, the underlying mechanism remains unclear. We hy...
Eligibility Criteria
Inclusion
- Subjects diagnosed with T2D on stable antidiabetic medication
- No recent use of SGLT2 inhibitor within 3 months
Exclusion
- HbA1c \> 10%
- Pregnancy or breast feeding
- estimated GFR \<45 30 mL/min/1.73㎡
- insulin user
Key Trial Info
Start Date :
January 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT05194592
Start Date
January 7 2022
End Date
June 30 2025
Last Update
August 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei University Wonju College of Medicine
Wŏnju, Gangwondo, South Korea, 26426